Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has sent a notice of allowance (NOA) regarding a patent application covering Prolor Biotech's CTP-modified interferons.
Subscribe to our email newsletter
The company applies its patented Carboxyl Terminal Peptide (CTP) technology and its Reversible Pegylation technology to develop longer-acting, proprietary versions of already approved therapeutic proteins.
The CTP technology is applicable to all proteins and the Reversible Pegylation technology is well-suited for use with peptides and small molecule therapeutics.
Interferons like alfa and beta are proteins produced in response to the presence of tumor cells or pathogens and are used to treat hepatitis B and C virus infections, multiple sclerosis and hematological malignancies, such as leukemia and lymphomas.
Prolor president Shai Novik said once issued, these allowances should strengthen the intellectual property portfolio that they are creating around their CTP technology.